1.	Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S) Phase: Phase IV Type: Treatment Status: Closed Age: Not specified Sponsor: Pharmaceutical / Industry Protocol IDs: HAL01S, NCT01463891
2.	E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7389-G000-301, NCT00337103
3.	E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7389-G000-305, NCT00388726
4.	A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7389-G000-302, NCT01454934
5.	Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7389-701, 2009-016047-19, NCT01126736
6.	A Phase 1b/2, Multicenter, Randomized, Open-Label, Dose-Escalation and Confirmation Study of Eribulin in Combination With Capecitabine Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7389-E044-203, NCT01323530
7.	A Study of E7389 in Advanced/Metastatic Breast Cancer Patients Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7389-A001-201, NCT00097721
8.	Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7389-A001-202, NCT00100932
9.	A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7389-G000-211, NCT00246090
10.	Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7389-G000-204, NCT00278993
11.	S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000481530, U10CA032102, S0618, SWOG-S0618, NCT00337129
12.	Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00169, 06-027, CDR0000481534, N01CM17105, MSKCC-06027, 7431, NCI-7431, NCT00334893
13.	Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00566, E5805, U10CA021115, CDR0000482413, ECOG-E5805, NCT00337077
14.	Eribulin Mesylate as Second-Line Therapy in Treating Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00173, PHL-049, CDR0000502291, N01CM62203, PMH-PHL-049, 7448, NCI-7448, NCT00383760
15.	E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-01159, PHII-74, CDR0000514516, N01CM62204, N01CM62201, N01CM62209, CCC-PHII-74, 7437, NCT00400829
16.	Phase II Study of E7389 in Patients With Advanced and/or Metastatic Soft Tissue Sarcoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: EORTC-62052, EISAI-E7389-E044-207, EUDRACT-2005-004272-20, NCT00413192
17.	A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer Phase: Phase II Type: Supportive care, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7389-G000-209, NCT00879086
18.	Continuation Study of E7389 for Advanced or Relapsed Breast Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 20 to 74 Sponsor: Pharmaceutical / Industry Protocol IDs: E7389-J081-224, NCT00965523
19.	Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7389-G000-205, NCT01104155
20.	A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7389-A001-206, NCT01268150
21.	Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7389-A001-208, NCT01269346
22.	Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: NU 10B07, NCI-2011-00600, STU00045038, NCT01372579
23.	A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 14392, 14T-IE-JVCD, CP12-1134, NCT01427933
24.	Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7389-A001-212, NCT01439282
25.	An Open Label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced Soft Tissue Sarcoma (Study E7389-J081-217) Phase: Phase II Type: Treatment Status: Closed Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7389-J081-217, NCT01458249